Top

Published in:

01-04-2018 | Original Paper

Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration

Authors: Mathilde Small, Isabelle Treilleux, Coline Couillault, Daniel Pissaloux, Géraldine Picard, Sandrine Paindavoine, Valery Attignon, Qing Wang, Véronique Rogemond, Stéphanie Lay, Isabelle Ray-Coquard, Jacobus Pfisterer, Florence Joly, Andreas Du Bois, Dimitri Psimaras, Nathalie Bendriss-Vermare, Christophe Caux, Bertrand Dubois, Jérôme Honnorat, Virginie Desestret

Published in: Acta Neuropathologica | Issue 4/2018

Abstract

Paraneoplastic cerebellar degenerations with anti-Yo antibodies (Yo-PCD) are rare syndromes caused by an auto-immune response against neuronal antigens (Ags) expressed by tumor cells. However, the mechanisms responsible for such immune tolerance breakdown are unknown. We characterized 26 ovarian carcinomas associated with Yo-PCD for their tumor immune contexture and genetic status of the 2 onconeural Yo-Ags, CDR2 and CDR2L. Yo-PCD tumors differed from the 116 control tumors by more abundant T and B cells infiltration occasionally organized in tertiary lymphoid structures harboring CDR2L protein deposits. Immune cells are mainly in the vicinity of apoptotic tumor cells, revealing tumor immune attack. Moreover, contrary to un-selected ovarian carcinomas, 65% of our Yo-PCD tumors presented at least one somatic mutation in Yo-Ags, with a predominance of missense mutations. Recurrent gains of the CDR2L gene with tumor protein overexpression were also present in 59% of Yo-PCD patients. Overall, each Yo-PCD ovarian carcinomas carried at least one genetic alteration of Yo-Ags. These data demonstrate an association between massive infiltration of Yo-PCD tumors by activated immune effector cells and recurrent gains and/or mutations in autoantigen-encoding genes, suggesting that genetic alterations in tumor cells trigger immune tolerance breakdown and initiation of the auto-immune disease.

Available only for authorised users

Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB (1998) Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 4:1321–1324. https://doi.org/10.1038/3315 CrossRefPubMed

Albert ML, Darnell RB (2004) Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 4:36–44. https://doi.org/10.1038/nrc1255 CrossRefPubMed

Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, Banchereau J (1999) In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190:1417–1426CrossRefPubMedPubMedCentral

Carpenter EL, Vance BA, Klein RS, Voloschin A, Dalmau J, Vonderheide RH (2008) Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration. J Neuroimmunol 193:173–182. https://doi.org/10.1016/j.jneuroim.2007.10.014 CrossRefPubMed

Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB (1997) A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci 17:1406–1415PubMed

Darnell JC, Albert ML, Darnell RB (2000) Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Can Res 60:2136–2139

Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–1554. https://doi.org/10.1056/NEJMra023009 CrossRefPubMed

Dieu-Nosjean M-C, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, Lebecque S, Fridman W-H, Cadranel J (2008) Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26:4410–4417. https://doi.org/10.1200/JCO.2007.15.0284 CrossRefPubMed

Eichler TW, Totland C, Haugen M, Qvale TH, Mazengia K, Storstein A, Haukanes BI, Vedeler CA (2013) CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLoS One 8:e66002. https://doi.org/10.1371/journal.pone.0066002 CrossRefPubMedPubMedCentral

10.

Engelhorn ME, Guevara-Patiño JA, Noffz G, Hooper AT, Lou O, Gold JS, Kappel BJ, Houghton AN (2006) Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 12:198–206. https://doi.org/10.1038/nm1363 CrossRefPubMed

11.

Frischmeyer PA, Dietz HC (1999) Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 8:1893–1900CrossRefPubMed

12.

Furneaux HF, Reich L, Posner JB (1990) Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology 40:1085–1091CrossRefPubMed

13.

Graus F, Dalmou J, René R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Viñolas N, Garcia del Muro J, Vadell C, Mason WP, Rosell R, Posner JB, Real FX (1997) Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 15:2866–2872. https://doi.org/10.1200/JCO.1997.15.8.2866 CrossRefPubMed

14.

Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren JJGM, Vincent A, Voltz R (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135–1140. https://doi.org/10.1136/jnnp.2003.034447 CrossRefPubMedPubMedCentral

15.

Hoxha E, Wiech T, Stahl PR, Zahner G, Tomas NM, Meyer-Schwesinger C, Wenzel U, Janneck M, Steinmetz OM, Panzer U, Harendza S, Stahl RAK (2016) A mechanism for cancer-associated membranous nephropathy. N Engl J Med 374:1995–1996. https://doi.org/10.1056/NEJMc1511702 CrossRefPubMed

16.

Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343:152–157. https://doi.org/10.1126/science.1246886 CrossRefPubMed

17.

Kim WK, Park M, Park M, Kim YJ, Shin N, Kim HK, You KT, Kim H (2013) Identification and selective degradation of neopeptide-containing truncated mutant proteins in the tumors with high microsatellite instability. Clin Cancer Res 19:3369–3382. https://doi.org/10.1158/1078-0432.CCR-13-0684 CrossRefPubMed

18.

Kottke T, Shim KG, Alonso-Camino V, Zaidi S, Maria Diaz R, Pulido J, Thompson J, Rajani KR, Evgin L, Ilett E, Pandha H, Harrington K, Selby P, Melcher A, Vile R (2016) Immunogenicity of self tumor associated proteins is enhanced through protein truncation. Mol Ther Oncolytics 3:16030. https://doi.org/10.1038/mto.2016.30 CrossRefPubMedPubMedCentral

19.

Kroeger DR, Milne K, Nelson BH (2016) Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin Cancer Res 22:3005–3015. https://doi.org/10.1158/1078-0432.CCR-15-2762 CrossRefPubMed

20.

Kurman RJ, Carcangiu ML, Herrington CS, Young RH (2014) WHO classification of tumours of female reproductive organs, 4th edn. World Health Organization, Geneva

21.

Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, Welters MJP, van der Burg S, Kapiteijn E, Michielin O, Romano E, Linnemann C, Speiser D, Blank C, Haanen JB, Schumacher TN (2014) Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 6:254ra128–254ra128. https://doi.org/10.1126/scitranslmed.3008918 CrossRefPubMed

22.

Leary JA, Kerr J, Chenevix-Trench G, Doris CP, Hurst T, Houghton CR, Friedlander ML (1995) Increased expression of the NME1 gene is associated with metastasis in epithelial ovarian cancer. Int J Cancer 64:189–195CrossRefPubMed

23.

Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, ESMO Guidelines Working Group (2013) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi24–vi32. https://doi.org/10.1093/annonc/mdt333 CrossRefPubMed

24.

Martinet L, Filleron T, Le Guellec S, Rochaix P, Garrido I, Girard J-P (2013) High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer. J Immunol 191:2001–2008. https://doi.org/10.4049/jimmunol.1300872 CrossRefPubMed

25.

Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, Rimoldi D, Liénard D, Gugerli O, Ferradini L, Robert C, Avril M-F, Zitvogel L, Angevin E (2004) Selective accumulation of mature DC-Lamp + dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Can Res 64:2192–2198CrossRef

26.

Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH (2012) CD20+ tumor-infiltrating lymphocytes have an atypical CD27− memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 18:3281–3292. https://doi.org/10.1158/1078-0432.CCR-12-0234 CrossRefPubMed

27.

Pastor F, Kolonias D, Giangrande PH, Gilboa E (2010) Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465:227–230. https://doi.org/10.1038/nature08999 CrossRefPubMedPubMedCentral

28.

Peterson K, Rosenblum MK, Kotanides H, Posner JB (1992) Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42:1931–1937CrossRefPubMed

29.

Raspaglio G, Petrillo M, Martinelli E, Li Puma DD, Mariani M, De Donato M, Filippetti F, Mozzetti S, Prislei S, Zannoni GF, Scambia G, Ferlini C (2014) Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness. Gene 542:173–181. https://doi.org/10.1016/j.gene.2014.03.037 CrossRefPubMed

30.

Rojas-Marcos I, Picard G, Chinchón D, Gelpi E, Psimaras D, Giometto B, Delattre JY, Honnorat J, Graus F (2012) Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo-associated paraneoplastic cerebellar degeneration. Neuro-oncology 14:506–510. https://doi.org/10.1093/neuonc/nos006 CrossRefPubMedPubMedCentral

31.

Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, Duarte SDV, Rivas MA, Warren-Perry M, Zachariou A, Campion-Flora A, Hanks S, Murray A, Ansari Pour N, Douglas J, Gregory L, Rimmer A, Walker NM, Yang T-P, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Eccles D, Evans DG, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Gore M, Houlston R, Brown MA, Caufield MJ, Deloukas P, McCarthy MI, Todd JA, Breast and Ovarian Cancer Susceptibility Collaboration, Wellcome Trust Case Control Consortium, Turnbull C, Reis-Filho JS, Ashworth A, Antoniou AC, Lord CJ, Donnelly P, Rahman N (2013) Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature 493:406–410. https://doi.org/10.1038/nature11725 CrossRefPubMed

32.

Santomasso BD, Roberts WK, Thomas A, Williams T, Blachère NE, Dudley ME, Houghton AN, Posner JB, Darnell RB (2007) A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci USA 104:19073–19078CrossRefPubMedPubMedCentral

33.

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen Y-T, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8 +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538–18543. https://doi.org/10.1073/pnas.0509182102 CrossRefPubMedPubMedCentral

34.

Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA (2014) Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol 128:835–852. https://doi.org/10.1007/s00401-014-1351-6 CrossRefPubMedPubMedCentral

35.

Storstein A, Krossnes BK, Vedeler CA (2009) Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand 120:64–67. https://doi.org/10.1111/j.1600-0404.2008.01138.x CrossRefPubMed

36.

Stumpf M, Hasenburg A, Riener M-O, Jütting U, Wang C, Shen Y, Orlowska-Volk M, Fisch P, Wang Z, Gitsch G, Werner M, Lassmann S (2009) Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer 101:1513–1521. https://doi.org/10.1038/sj.bjc.6605274 CrossRefPubMedPubMedCentral

37.

Sutton IJ, Steele J, Savage CO, Winer JB, Young LS (2004) An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies. J Neuroimmunol 150:98–106. https://doi.org/10.1016/j.jneuroim.2003.12.026 CrossRefPubMed

38.

Tanaka K, Tanaka M, Onodera O, Tsuji S (1995) Paraneoplastic cerebellar degeneration—characterization of anti-Yo antibody and underlying cancer. Rinsho Shinkeigaku 35:770–774PubMed

39.

Tanaka M, Tanaka K, Onodera O, Tsuji S (1995) Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin Neurol Neurosurg 97:95–100CrossRefPubMed

40.

Totland C, Aarskog NK, Eichler TW, Haugen M, Nøstbakken JK, Monstad SE, Salvesen HB, Mørk S, Haukanes BI, Vedeler CA (2011) CDR2 antigen and Yo antibodies. Cancer Immunol Immunother 60:283–289. https://doi.org/10.1007/s00262-010-0943-9 CrossRefPubMed

41.

Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA (2015) Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350:207–211. https://doi.org/10.1126/science.aad0095 CrossRefPubMedPubMedCentral

42.

Verschuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, Dalmau J (1996) Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta Neuropathol 91:519–525CrossRefPubMed

43.

Zaborowski MP, Spaczynski M, Nowak-Markwitz E, Michalak S (2015) Paraneoplastic neurological syndromes associated with ovarian tumors. J Cancer Res Clin Oncol 141:99–108. https://doi.org/10.1007/s00432-014-1745-9 CrossRefPubMed

44.

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203–213. https://doi.org/10.1056/NEJMoa020177 CrossRefPubMed

Title: Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration
Authors: Mathilde Small
Isabelle Treilleux
Coline Couillault
Daniel Pissaloux
Géraldine Picard
Sandrine Paindavoine
Valery Attignon
Qing Wang
Véronique Rogemond
Stéphanie Lay
Isabelle Ray-Coquard
Jacobus Pfisterer
Florence Joly
Andreas Du Bois
Dimitri Psimaras
Nathalie Bendriss-Vermare
Christophe Caux
Bertrand Dubois
Jérôme Honnorat
Virginie Desestret
Publication date: 01-04-2018
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 4/2018
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-017-1802-y

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Integrated neurodegenerative disease autopsy diagnosis

The referee who agrees to review and never responds again (NERO): a series of 37 cases of an emerging entity

5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma

T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression

Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation

Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis